Humacyte (HUMA) Assets Average (2020 - 2026)
Humacyte (HUMA) posted quarterly Assets Average of $113.5 million for Q1 2026, down 24.47% year-over-year from $150.2 million in Q1 2025, and up 9.16% quarter-over-quarter from $103.9 million in Q4 2025.
Humacyte (HUMA) Assets Average (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Assets Average for 7 consecutive years, with $113.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 24.47% year-over-year to $113.5 million; the TTM figure through Mar 2026 stood at $113.5 million (down 24.47% YoY), while the FY2025 annual figure was $127.1 million, down 4.46% from the prior year.
- Assets Average rose to $113.5 million in Q1 2026 per HUMA's latest filing, from $103.9 million in the prior quarter.
- Across five years, Assets Average topped out at $275.5 million in Q1 2022 and bottomed at $103.9 million in Q4 2025.
- Historically, Assets Average has averaged $166.5 million across 5 years, with a median of $150.2 million in 2025.
- Annual changes were most pronounced in 2022 — Assets Average surged 165.73% — and 2023, when it tumbled 35.52%.
- Humacyte's Assets Average stood at $215.3 million in 2022, then sank by 35.52% to $138.8 million in 2023, then retreated by 9.0% to $126.3 million in 2024, then decreased by 17.72% to $103.9 million in 2025, then advanced by 9.16% to $113.5 million in 2026.
- Business Quant data shows HUMA's Assets Average at $113.5 million in Q1 2026, $103.9 million in Q4 2025, and $115.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 124.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.32 Mn |
| Mar 31, 2026 | 113.46 Mn |
| Dec 31, 2025 | 103.94 Mn |
| Sep 30, 2025 | 115.15 Mn |
| Jun 30, 2025 | 150.67 Mn |
| Mar 31, 2025 | 150.21 Mn |
| Dec 31, 2024 | 126.32 Mn |
| Sep 30, 2024 | 126.52 Mn |
| Jun 30, 2024 | 149.87 Mn |
| Mar 31, 2024 | 144.84 Mn |
| Dec 31, 2023 | 138.80 Mn |
| Sep 30, 2023 | 158.75 Mn |
| Jun 30, 2023 | 175.54 Mn |
| Mar 31, 2023 | 193.64 Mn |
| Dec 31, 2022 | 215.26 Mn |
| Sep 30, 2022 | 236.29 Mn |
| Jun 30, 2022 | 255.42 Mn |
| Mar 31, 2022 | 275.50 Mn |
| Dec 31, 2021 | 294.95 Mn |
| Sep 30, 2021 | 201.94 Mn |